Literature DB >> 18758218

[11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study.

Ludwig Rinnab1, Felix M Mottaghy, Joerg Simon, Bjoern G Volkmer, Robert de Petriconi, Richard E Hautmann, Markus Wittbrodt, Guenther Egghart, Peter Moeller, Norbert Blumstein, Sven Reske, Rainer Kuefer.   

Abstract

INTRODUCTION: In this prospective study we set out to investigate the diagnostic value of [(11)C]choline-PET/CT in patients with suspected lymph node metastases before salvage lymph node dissection. PATIENTS AND METHODS: 15 consecutive patients with rising PSA underwent [(11)C]choline-PET/CT and consecutive open salvage pelvic/retroperitoneal extended lymph node dissection due to uptake of [(11)C]choline in at least 1 lymph node. Mean age was 62.1 (range 53-73).
RESULTS: [(11)C]choline-PET/CT results were compared with the histopathology reports and clinical follow-up (mean 13.7 months, range 6-24). Mean time to progression was 23.6 months (range 4-81). [(11)C]choline uptake was observed in nodes along the external and internal and common iliac arteries and in the paraaortic region. A positive histology was reported in 8/15 patients. Only one patient had a PSA nadir of <0.1 ng/ml after salvage surgery. Another patient had stable disease with a PSA of 0.5 ng/ml. Three patients developed bone metastases during follow-up.
CONCLUSIONS: This interim analysis indicates that [(11)C]choline-PET/CT may be a useful technique in detection of lymph node metastases when rising PSA occurs after definite prostate cancer therapy. The presented cohort is limited in size, but there is still strong evidence that the patients benefit from [(11)C]choline-PET/CT and consecutive salvage lymph node dissection is rather small. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18758218     DOI: 10.1159/000144059

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  29 in total

1.  Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy.

Authors:  Christoph Henkenberens; Axel S Merseburger; Frank Bengel; Thorsten Derlin; Katja Hueper; Viktor Grünwald; Hans Christiansen
Journal:  World J Urol       Date:  2015-11-27       Impact factor: 4.226

2.  (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.

Authors:  Christoph Henkenberens; Christoph A von Klot; Tobias L Ross; Frank M Bengel; Hans-Jürgen Wester; Axel S Merseburger; Jens Vogel-Claussen; Hans Christiansen; Thorsten Derlin
Journal:  Strahlenther Onkol       Date:  2016-06-07       Impact factor: 3.621

Review 3.  Clinical oncologic applications of PET/MRI: a new horizon.

Authors:  Sasan Partovi; Andres Kohan; Christian Rubbert; Jose Luis Vercher-Conejero; Chiara Gaeta; Roger Yuh; Lisa Zipp; Karin A Herrmann; Mark R Robbin; Zhenghong Lee; Raymond F Muzic; Peter Faulhaber; Pablo R Ros
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

Review 4.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

5.  Interim analyses in diagnostic versus treatment studies: differences and similarities.

Authors:  Oke Gerke; Poul Flemming Høilund-Carlsen; Mads Hvid Poulsen; Werner Vach
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-10

Review 6.  Experimental models to study lymphatic and blood vascular metastasis.

Authors:  Lu Chen; Byron Hann; Lily Wu
Journal:  J Surg Oncol       Date:  2011-05-01       Impact factor: 3.454

7.  Can (68)GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?

Authors:  Fabio Zattoni; Andrea Guttilla; Laura Evangelista
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-23       Impact factor: 9.236

Review 8.  Surgical resection of urological tumor metastases following medical treatment.

Authors:  Axel Heidenreich; Stefan Wilop; Michael Pinkawa; Daniel Porres; David Pfister
Journal:  Dtsch Arztebl Int       Date:  2012-09-28       Impact factor: 5.594

Review 9.  PET imaging for lymph node dissection in prostate cancer.

Authors:  Elena Incerti; Paola Mapelli; Luigi Gianolli; Maria Picchio
Journal:  World J Urol       Date:  2016-10-17       Impact factor: 4.226

10.  Modalities for imaging of prostate cancer.

Authors:  A H Hou; D Swanson; A B Barqawi
Journal:  Adv Urol       Date:  2010-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.